Coinfection of Strongyloides stercoralis and Aspergillus sp.
Conclusion. The case highlights the features of concomitant infection of S. stercoralis and Aspergillus in immunocompromised patients and the importance of screening patients for strongyloidiasis before initiation of immunosuppressive therapy. PMID: 32565789 [PubMed]
CONCLUSIONS: There is lack of evidence for the efficacy and safety of anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis. There is a need for large prospective randomized controlled studies of anti-IgE therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis with both clinical and laboratory outcome measures such as steroid requirement, allergic bronchopulmonary aspergillosis exacerbations and lung function.PMID:34550603 | DOI:10.1002/14651858.CD010288.pub5
CONCLUSION: Aspergillus endocarditis is rare but is associated with a very high mortality rate. Knowledge of its predictive factors and key clinical features can help to differentiate aspergillosis from non-fungal endocarditis and may enable improved survival rates.PMID:34303547 | DOI:10.1016/j.revmed.2021.07.001
CONCLUSION: Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.PMID:34174797 | DOI:10.3906/sag-2104-227
We report a case of ABPA in a woman without a known history of asthma. She presented an acute bronchitis with wheezing dyspnea leading to an acute respiratory failure. She was hospitalized in the intensive care unit. The bronchoscopy revealed a complete obstruction of the left primary bronchus by a sticky greenish material. The culture of this material isolated Aspergillus fumigatus and that of bronchial aspiration fluid isolated Pseudomonas aeruginosa. The diagnosis of ABPA was based on elevated eosinophil count, the presence of specific IgE and IgG against Aspergillus fumigatus and left segmental collapse on chest comput...
CONCLUSIONS: Alternative treatment modalities for ABPA in patients with CF, including azole antifungals, pulsed intravenous glucocorticoids, omalizumab, mepolizumab, and inhaled amphotericin, appear to be efficacious and well tolerated. Pharmacological properties including route of administration, storage and stability, beyond use dating, and adverse effects of the various treatment modalities must be considered when selecting a practical care plan for patients.PMID:34078140 | DOI:10.1177/10600280211022065
CONCLUSION: The diagnosis of ABPA in CF should be based on more standardized biological assays and imaging to optimize treatment and follow-up.PMID:33926779 | DOI:10.1016/j.rmr.2021.04.004
Conclusions. A substantial number of patients with pretransplant Aspergillus colonization can still undergo successful liver transplantation if they are otherwise suitable candidates and receive appropriate antifungal prophylaxis. Posttransplant outcome in these patients is determined mostly by noninfectious complications and not fungal infection. Pretransplant Aspergillus colonization alone should not necessarily preclude or delay liver transplantation.
Authors: Kurihara Y, Tashiro H, Takahashi K, Komiya N, Sadamatsu H, Kimura S, Sueoka-Aragane N Abstract Allergic bronchopulmonary aspergillosis (ABPA) is a severe form of asthma in which structural airway destruction occurs due to a hypersensitivity reaction to fungi. A 25-year-old man without any major features of asthma had lung infiltration with dilatation of the central bronchus, high-attenuation mucus with histological eosinophilic invasion, fungi detected on cultures, and positive Aspergillus-specific immunoglobulin E (IgE) and precipitating antibody of Aspergillus, with a significant elevation of blood eosin...
Invasive aspergillosis is rare in immunocompetent individuals. Aspergillus infection seldom results in cardiac involvement, but can be associated with pancarditis, myocardial abscess or granuloma formation, and typically occurs in patients who are immunocompromised, have undergone recent cardiac surgery, or have prolonged corticosteroid use.
We report two cases of patients with allergic SA who developed ABPA relapse after omalizumab withdrawal. Both patients had chronic bronchiectasis and moderate lung fibrosis consistent with chronic pulmonary aspergillosis (CPA). MS, male 63 yrs, had had 2 ABPA episodes in the year before starting OMA, and needed chronic prednisone 25 mg daily. During 1 yr OMA no ABPA episode occurred despite reducing prednisone to 5 mg. ABPA relapsed two months after he stopped OMA due to long stay abroad. GF, male 73 yrs, had had several ABPA episodes until june 2015 when OMA was prescribed. During 2 yrs OMA treatment no ABPA episode occur...